Format

Send to

Choose Destination
PLoS One. 2018 Mar 15;13(3):e0194016. doi: 10.1371/journal.pone.0194016. eCollection 2018.

Establishment of patient-derived tumor spheroids for non-small cell lung cancer.

Author information

1
Department of Respiration, The Second Affiliated Hospital of Soochow University, Suzhou, P.R. China.
2
Invitrocue Biomedical Service Suzhou, Suzhou, P.R. China.
3
Department of Thoracic & Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, P.R. China.
4
Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, P.R. China.
5
Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.

Abstract

The prognosis of advanced non-small cell lung cancer (NSCLC) patients is poor. One of the reasons for this hampered progress has been a lack of in vitro models that would faithfully recapitulate the heterogeneity of tumors and response to treatment. In this study, surgically resected tumors were obtained from patients with stage I/II NSCLC during curative-intent surgery. Using a 3D patient-derived tumor spheroids culture system, our results demonstrate successful long-term expansion of primary NSCLC cells in vitro (> 120 days). Patient-derived tumor spheroid (PDS) cultures could be established with a success rate of 100% (3 out of 3 samples). Consistent with their growth in culture and their cancer type, many cells within the tumor spheroids were stained positive for Ki67 and thyroid transcription factor-1. The result of this study supports the establishment of an expandable 3D in vitro NSCLC model for drug screening, and enables the potential long term studies such as the establishment of drug resistant models.

PMID:
29543851
PMCID:
PMC5854348
DOI:
10.1371/journal.pone.0194016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center